SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ --I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. phase 2 dose expansion clinical study of its proprietary CD73 antibody uliledlimab (also known as TJD5) in combination with atezolizumab (Tecentriq
